Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

September 1, 2018

Study Completion Date

May 7, 2019

Conditions
Diabetes Mellitus Type 1
Interventions
DRUG

GNbAC1

Monthly IV repeated dose

DRUG

Placebo

Monthly IV repeated dose

Trial Locations (13)

Unknown

Macquarie University Hospital, Macquarie University

AIM Centre, Merewether

Northern Sydney Local Health District - Royal North Shore Hospital, St Leonards

Ipswich Research Centre, Ipswich

Mater Misericordiae Ltd and Mater Medical Research Institute Limited, South Brisbane

Gold Coast Hospital and Health Service, Southport

Southern Adelaide Local Health Network - Repatriation General Hospital, Adelaide

Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital, Elizabeth Vale

Eastern Health, Box Hill

St Vincent's Hospital (Melbourne) Limited, Fitzroy

Barwon Health - University of Geelong, Geelong

Heidelberg Repatriation Hospital, Heidelberg

Keogh Institute of Medical Research, Nedlands

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Southern Star Research

INDUSTRY

lead

GeNeuro Australia PTY Ltd

INDUSTRY

NCT03179423 - Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years | Biotech Hunter | Biotech Hunter